摘要
在病毒害肆虐的贫困地区他被视为天使，但在欧洲和美国一些专利药巨头眼中他有如“海盗”。
Why Yusuf Hamicd is regarded as angel in the eyes of the HIV/AIDS infectors in Africa and Latin America. but a deadly enemy for the multinational pharmaceutical companies like GlaxoSmithKlinc, Pfizer and Bristol-Myers Squibb. The Indian and his company Cipla had created a stir in the global anti-AlDS drugs market in March 2001, by offering a triple drug cocktail at low price (US $350) per patient per year. At that time, the anti-AIDS drugs market was controlled by a few pharmaceutical giants who own the patent rights and the medicine cost was as high as 10,000-15.000 US dollars per patient per year. Now Hamicd is trying to lobby Chinese government with Chinese pharmaceutical company Desano ,and launch a new round of cooperation between Indian and Chinese pharmaceutical manufacturers.
出处
《中国企业家》
2006年第19期74-77,6,共4页
China Entrepreneur
